Cristina Suárez - Concepedia

Author

Cristina Suárez

Vall d'Hebron Hospital Universitari ORCID

Also Known As

Albert Font Pous, C Padilla Suarez, C Suarez, C Suárez, C. Padilla Suárez, C. Pinto Suarez, C. Suarez, C. Suárez, C., Suarez, C.P. Suarez

367

Publications

14K

Citations

H-Index

118

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Vall d'Hebron Institute of Oncology Queen Mary University of London Institut Gustave Roussy Universitat Autònoma de Barcelona

About

Cristina Suárez is an author at Vall d'Hebron Hospital Universitari specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	64	6.9K
2	Health Sciences	13	18	931
3	Natural Sciences	5	5	85
4	Engineering	3	3	58
5	Nursing	1	1	174

Cristina Suárez

118

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Toni K. Choueiri, Thomas Powles, Mauricio Burotto, New England Journal of Medicine	2021	1.6K
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Nature Medicine UrologyGenitourinary CancerMedicinePathologyBevacizumab Versus Sunitinib	2018	1.2K
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Brian I. Rini, Thomas Powles, Michael B. Atkins, The Lancet UrologyGenitourinary CancerMedicineBevacizumab Versus SunitinibImmune Checkpoint Inhibitor	2019	988
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida, Nature Medicine UrologyBiomarker AnalysisGenitourinary CancerMedicineCancer Treatment	2019	555
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, The Lancet Oncology Surgical OncologyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2020	485
Health Care–Associated Pneumonia Requiring Hospital Admission Jordi Carratalà, Analía Mykietiuk, Núria Sabé, Archives of Internal Medicine	2007	320
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial Robert J. Motzer, Thomas Powles, Mauricio Burotto, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyCabozantinib Versus Sunitinib	2022	286
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Journal of Clinical Oncology	2021	277
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer Thomas Powles, James W.F. Catto, Matthew D. Galsky, New England Journal of Medicine	2024	245
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up T. Powles, Laurence Albigès, Axel Bex, Annals of Oncology	2024	222

Page 1